Celcuity presents preclinical data on therapeutic effects of gedatolisib

Celcuity presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium. The preclinical studies evaluated gedatolisib, a pan-PI3K/mTOR inhibitor, and PAM inhibitors that selectively target single PAM nodes to compare the functional effect of inhibiting multiple vs. single PAM pathway nodes in a panel of breast cancer cell lines. In cell viability and proliferation analyses, gedatolisib was found to be more cytotoxic and at least 300-fold more potent, on average, compared to the single node PAM inhibitors. Mechanistically, gedatolisib decreased cell survival, DNA replication, protein synthesis, glucose consumption, lactate production and oxygen consumption more effectively than the other PAM inhibitors. In vivo studies confirmed that pan-PI3K/mTOR inhibition by gedatolisib reduced tumor cell growth more effectively than single node inhibitors in breast cancer patient derived xenograft models with and without PAM pathway mutations.